Home
Clinical Trials
An Effectiveness Study Compar...

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

Last Updated: 2019-01-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

4233 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-01

Study Completion Date

2016-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848

Asthma

COMPLETED PHASE3

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

NCT01686633

Asthma

COMPLETED PHASE3

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

NCT01128569

Asthma

COMPLETED PHASE2

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

NCT03363191

Asthma

WITHDRAWN PHASE4

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01134042

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase III multi-centre, randomised open label study performed in subjects followed in primary care who have a diagnosis of and receive regular treatment for asthma in a localised geographical region of the UK

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FF/VI

fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler

Group Type EXPERIMENTAL

fluticasone furoate + vilanterol

Intervention Type DRUG

once daily via a Novel Dry Powder Inhaler

inhaled corticosteroid with or without a long acting beta2-agonist

Intervention Type DRUG

ICS alone or in combination with a long acting bronchodilator

ICS or ICS/LABA maintenance therapy

inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)

Group Type ACTIVE_COMPARATOR

inhaled corticosteroid with or without a long acting beta2-agonist

Intervention Type DRUG

ICS alone or in combination with a long acting bronchodilator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluticasone furoate + vilanterol

once daily via a Novel Dry Powder Inhaler

Intervention Type DRUG

inhaled corticosteroid with or without a long acting beta2-agonist

ICS alone or in combination with a long acting bronchodilator

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects eligible for enrolment in the study must meet all of the following criteria:

1. Informed consent: Subjects must be able to provide informed consent, have their consent signed and dated.
2. Type of subject: Subjects with documented GP diagnosis of asthma as their primary respiratory disease.
3. Current Anti-Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS with or without LABA (either a fixed combination or via separate inhalers), and for at least 4 weeks prior to Visit 2.

* Other background asthma medication such as anti-leukotrienes are permitted
4. All subjects on ICS monotherapy or ICS/LABA combination (this can be a fixed dose combination or an ICS alone or LABA alone in separate inhalers) must have had symptoms in the past week prior to Visit 2. Symptoms are defined by daytime symptoms more than twice per week, use of short-acting beta2-agonist bronchodilator more than twice per week, any limitation of activities, or any nocturnal symptoms/awakening. (The symptoms are based on subject's recall and are consistent with the GINA and in principal with the BTS/SIGN guidelines).
5. Subject questionnaires: Subjects must be able to complete the electronic subject questionnaires as well as those questionnaires that are completed by phone or provide a proxy e.g. a partner/relative/a friend who can do so on their behalf
6. Gender and Age: Male or female subjects aged ≥18 years of age at Visit 1. A female is eligible to enter and participate in the study if she is of:

* Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH \> 40MIU/ml and estradiol \<40pg/ml (\<147 pmol/L) is confirmatory.

OR Child bearing potential has a negative urine pregnancy test at Visit 2, and agrees to one of the highly effective and acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - Visit 2 to the end of the study).

Exclusion Criteria

Subjects meeting any of the following criteria must not be enrolled in the study:

1. Recent history of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months.
2. COPD Respiratory Disease: A subject must not have current evidence or GP diagnosis of chronic obstructive pulmonary disease.
3. Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the GP/ Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
4. Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta2-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the GP/ Investigator, contraindicates the subject's participation will also be excluded.
5. Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Visit 2 or within five half-lives (t½) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening)
6. Chronic user of systemic corticosteroids: A subject who, in the opinion of the GP/Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening)
7. Subjects who are using LABA without an ICS as asthma maintenance therapy.
8. Subjects who plan to move away from the geographical area where the study is being conducted during the study period and/or if subjects have not consented to their medical records being part of the electronic medical records database that is operational in the Salford area.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Altrincham, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Bowdon, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Cheadle, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Cheadle Hulme, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Edgeley, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Gatley, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Heald Green, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Sale, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Sale, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Sale, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Sale, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Stockport, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Timperley, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Timperley, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Greater Manchester, United Kingdom

Site Status

GSK Investigational Site

Altrincham, Greater Manchester, United Kingdom

Site Status

GSK Investigational Site

Broadway, Davyhulme, Greater Manchester, United Kingdom

Site Status

GSK Investigational Site

Irlam, Greater Manchester, United Kingdom

Site Status